Asensus Surgical

A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.Read the full explainer →

DEPLOY tracks the 2023 Asensus Senhance uncontrolled-arm Class I recall ↗ at primary-source-anchored FDA-recall-database verification depth as a software_defect Class I recall at Asensus Surgical pre-acquisition corporate-state context. The substrate: Class I recall September 15, 2023; software malfunction caused uncontrolled arm motion of the laparoscope instrument actuator, which rotated continuously in one direction after the surgeon disengaged teleoperation (critical-tissue-trauma risk; emergency stop available as mitigation); 5 US devices at exact verification depth; cease-use until software updated to v2.7.5; no patient harm reported; remediated. Root cause: software_defect (software malfunction; laparoscope instrument actuator rotated continuously after teleoperation was disengaged). The incident operates as the CANONICAL worked example for verified-vs-claimed at acquisition-state boundary granularity: 2023 incident occurred at Asensus Surgical pre-acquisition corporate-state; August 22, 2024 Karl Storz acquisition (full_acquisition structure + reported valuation_basis at ~$0.35/share per the acquisition history Project B methodology pillar) transitioned Senhance/LUNA product lines to Karl Storz subsidiary corporate-state. Completes the cross-cohort surgical quartet (2026 da Vinci SureForm gray-reload + within-da-Vinci year-discipline + 2021 ROSA ONE Brain wrong-trajectory + 2023 Asensus Senhance uncontrolled-arm) at canonical-reference depth + completes the three-incident software_defect-as-cross-cohort-root-cause-class structural composition (2021 ROSA ONE Brain + 2023 Asensus Senhance + 2024 Stryker Mako). Framework reads incident at primary-source-anchored verification depth across three-axis substrate composition pattern simultaneously: numerator (Class I + software_defect + recall_ordered + remediated) + denominator (5 US devices at exact verification; substantively higher-verification-completeness tier within broader cohort exposure_hours 128-nulls honest-absence) + scalar selectivity (no patient harm reported as substantive editorial state per banked honesty-as-strength editorial framing).Read the full explainer →